Suppressed CEBPA DNA binding function is associated with favorable outcome in NK-AML patients. (A) Waterfall diagram presentations of CEBPA DNA binding function assessed by ELISA in 105 consecutive AML patients with an NK. The cut-off of 0.094 represents the highest value observed among inv(16) and t(8;21) AML patients in Figure 1G. (B) Kaplan-Meier curves are shown for OS and (C) DFS comparing NK-AML patients with suppressed versus normal CEBPA DNA binding function.